Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.58 |
| ▸ | DEGS1 | O15121 | 5/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17052986 | 0.84 | ESR1 (0.61) | ESR1ESR2DEGS1PDCD1CD274 | |
| SCHEMBL3722303 | 0.82 | ESR1 (0.55) | ESR1ESR2DEGS1PDCD1CD274 | |
| SCHEMBL15022591 | 0.82 | ESR1 (0.55) | ESR1ESR2DEGS1PDCD1CD274 | |
| SCHEMBL15022592 | 0.82 | ESR1 (0.55) | ESR1ESR2DEGS1PDCD1CD274 | |
| SCHEMBL31119420 | 0.79 | ESR1 (0.51) | ESR1ESR2DEGS1PDCD1CD274 | |
| SCHEMBL9884975 | 0.79 | ESR1 (0.66) | ESR1ESR2DEGS1GRIN2B | |
| SCHEMBL2897054 | 0.78 | ESR1 (0.50) | ESR1ESR2GRIN2BGRIN1 | |
| SCHEMBL23963107 | 0.77 | ESR1 (0.50) | ESR1ESR2DEGS1PDCD1CD274 | |
| SCHEMBL30025101 | 0.76 | ESR1 (0.48) | ESR1ESR2GRIN2BGRIN1 | |
| SCHEMBL19555305 | 0.76 | ESR1 (0.48) | ESR1ESR2GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2025-04-10 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | disclosed |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| WO-2009140163-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK & CO., INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-6355805-B1 | MULTIBINDING COMPOUNDS USEFUL IN TREATMENT AND PREVENTION OF METABOLIC DISORDERS SUCH AS OBESITY AND DIABETES | ADVANCED MEDICINE, INC. | 2002-03-12 | — | — | US | disclosed |
| EP-1085894-A1 | BETA 3-ADRENERGIC RECEPTOR AGONISTS | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064053-A1 | β3-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | ESR1 3609/4885ESR2 2511/4885DEGS1 4293/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ESR1 1215/4885ESR2 2054/4885DEGS1 2037/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ESR1 1100/4885ESR2 482/4885DEGS1 2516/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | ESR1 927/4885ESR2 1919/4885DEGS1 1810/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ESR1 1100/4885ESR2 482/4885DEGS1 2516/4885 |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | ESR1 923/4885ESR2 311/4885DEGS1 3785/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | ESR1 560/4885ESR2 1326/4885DEGS1 1169/4885 |
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ESR1 1100/4885ESR2 482/4885DEGS1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.